Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘BLU-285’

Snow at GWCCAtlanta – it’s day 2 of the annual meeting of the American Society of Hematology (ASH) meeting here in a chilly and snowy Atlanta.

I have to confess snow is not something we normally associate with southern States such as Georgia, but a cold snap has taken it’s toll on the ASH meeting, with many presentations cancelled as a result of travel delays.

Sunday at ASH is well known for the plenary session that takes place in the afternoon, but what else is hot at the meeting today? We’ve been talking to thought leaders, spending time in the vast poster hall and hearing some oral abstracts. There’s been been a surprising amount going on today at ASH in Atlanta.

If you are at ASH then you’ll know that all the sessions end at the same time, resulting in a massive movement of people as they go to the next session, as we saw today:

 

To get a heads up and further insights from ASH, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

At the recent Triple (EORTC-NCI-AACR) and ASH meetings, Blueprint Medicines (Cambridge, MA) presented data on some of their targeted compounds in early clinical development including data in KIT, PDGFα and FGFR4 driven cancers.

While many observers attention is currently distracted on cancer immunotherapies, let’s not take our eye off the ball and forget that when we do find driver oncogenes in rare tumours, the activity of TKIs can still be superior in these situations and offer exquisite sensitivity, leading to exceptional responses.

Here, we take stock with a look what Blueprint are doing, where they’re going and also offer some perspectives from senior company executives, whom we interviewed last month.

Which reminds me, someone recently asked why we do so many interviews, “You do a prodigious amount of interviews on BSB, why is that?”

The answer is very simple – to learn faster and share that knowledge with other like minded souls. Charlie Ambler, author of Daily Zen, sums it up well in an essay about Talk Less:

“In Zen tradition, I’d like the kill the Buddha that is Lao Tzu and revise his ancient saying. It’s not that those who talk don’t know and those who know don’t talk— it’s that talking often inhibits us from knowing.”

Thus, the corollary here is that if you undertake interviews with scientists and researchers regularly then you have the pleasure of talking less – the person in the hotseat naturally talks more – and you learn faster.

What’s not to like? We all learn different things depending on our perspective and knowledge base. Sometimes, I even find re-reading old interviews a year or so later while preparing for a new one a related topic teaches me something new I didn’t see or realise before, simply because my own understanding has improved. Hopefully that is also true for subscribers!

To learn more insights about this promising small biotech, including an interview with company executives, subscribers can log-in

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!